These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17666913)

  • 1. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.
    Dorian P; Pinter A; Mangat I; Korley V; Cvitkovic SS; Beatch GN
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):35-40. PubMed ID: 17666913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig.
    Wiesfeld AC; De Langen CD; Crijns HJ; Bel KJ; Hillege HL; Wesseling H; Lie KI
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):594-600. PubMed ID: 8847879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial selective effects of intravenously administered vernakalant in conscious beagle dogs.
    Bechard J; Pourrier M
    J Cardiovasc Pharmacol; 2011 Jul; 58(1):49-55. PubMed ID: 21753258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs.
    Bechard J; Gibson JK; Killingsworth CR; Wheeler JJ; Schneidkraut MJ; Huang J; Ideker RE; McAfee DA
    J Cardiovasc Pharmacol; 2011 Mar; 57(3):302-7. PubMed ID: 21266917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate-dependent effects of diltiazem on human atrioventricular nodal properties.
    Talajic M; Lemery R; Roy D; Villemaire C; Cartier R; Coutu B; Nattel S
    Circulation; 1992 Sep; 86(3):870-7. PubMed ID: 1516199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiologic characteristics of the atrium in sinus node dysfunction: atrial refractoriness and conduction.
    De Sisti A; Leclercq JF; Fiorello P; Manot S; Halimi F; Attuel P
    J Cardiovasc Electrophysiol; 2000 Jan; 11(1):30-3. PubMed ID: 10695458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration.
    Touboul P; Atallah G; Kirkorian G; de Zuloaga C; Dufour A; Aymard MF; Lavaud P; Moleur P
    Am Heart J; 1986 Aug; 112(2):333-9. PubMed ID: 3526853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
    Camm AJ; Toft E; Torp-Pedersen C; Vijayaraman P; Juul-Moller S; Ip J; Beatch GN; Dickinson G; Wyse DG;
    Europace; 2012 Jun; 14(6):804-9. PubMed ID: 22291438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological effects of Org 7797 in the closed-chest anaesthetized dog.
    Leboeuf J; Basiez M; Massingham R
    Br J Pharmacol; 1993 Sep; 110(1):23-8. PubMed ID: 8220882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
    Naitoh N; Taneda K; Tagawa M; Furushima H; Yamaura M; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):297-305. PubMed ID: 9711181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I; Graydon R; Camm AJ
    Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle.
    Naitoh N; Furushima H; Ohira K; Taneda K; Aizawa Y
    Jpn Heart J; 1998 Mar; 39(2):153-61. PubMed ID: 9687824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.